An evaluation of normal saline and taurolidine on intra-abdominal adhesion formation and peritoneal fibrinolysis.
BACKGROUND
Intraoperative lavage with normal saline or taurolidine solutions is commonly used in abdominal surgery. For this purpose, normal saline and taurolidine, which may modify the intrinsic fibrinolytic activity of the peritoneum by breaking the peritoneal adhesions, are frequently used. We aimed to evaluate how normal saline and taurolidine affect peritoneal fibrinolysis and adhesion formation.


METHODS
A rat model of peritoneal adhesion was used. Control animals received no medication, while normal saline or taurolidine solutions were administered intraperitoneally to the remaining two groups (n = 20 for each group). At postoperative day 10 adhesions were graded, and cardinal parameters of peritoneal fibrinolysis (activities and concentrations of tissue plasminogen activator [tPA], plasminogen activator inhibitor type 1 [PAI-1], and tPA/PAI-1 complex), and hydroxyproline contents were determined in peritoneal tissue samples.


RESULTS
Total adhesion scores were decreased in both of the treated groups. Median tissue levels of tPA and tPA activity were higher in the treated groups versus controls. The PAI-1 levels were similar among the three groups. tPA/PAI-1 complex levels were higher in animals that received normal saline and in those treated with taurolidine solution compared with control animals. Peritoneal hydroxyproline levels were similar across the three groups.


CONCLUSIONS
Our results suggest that normal saline and taurolidine solution administrations might reduce peritoneal adhesion formation, probably by altering peritoneal fibrinolytic activity.
Tarhan
Omer Ridvan
OR
Department of General Surgery, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey. ortarhan@gmail.com
Barut
Ibrahim
I
Sezik
Mekin
M
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006909:Hydroxyproline / Q000378:metabolism; D010537:Peritoneum / Q000187:drug effects / Q000378:metabolism / Q000601:surgery*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D011183:Postoperative Complications / Q000517:prevention & control; D051381:Rats; D017208:Rats, Wistar; D012965:Sodium Chloride / Q000494:pharmacology*; D013654:Taurine / Q000031:analogs & derivatives* / Q000494:pharmacology; D007507:Therapeutic Irrigation; D013829:Thiadiazines / Q000494:pharmacology*; D000267:Tissue Adhesions / Q000517:prevention & control*; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D000970:Antineoplastic Agents; D017395:Plasminogen Activator Inhibitor 1; D013829:Thiadiazines; D013654:Taurine; D012965:Sodium Chloride; C012566:taurolidine; D010959:Tissue Plasminogen Activator; D006909:Hydroxyproline